Gilid signed an agreement with science and technology to deepen strategic cooperation in the areas of chronic hepatitis B, hepatitis C and HIV infection.

In November 17th, the European Union health center was informed that jillid science and Jinyu medicine formally signed a strategic cooperation agreement in the detection of chronic hepatitis B HBV DNA Gao Min test, hepatitis C routine screening, HIV (human immunodeficiency virus, or HIV) infection virus and renal function tests, as well as doctor education. Further deepen cooperation in public disease science popularization and patient education. Faced with tens of millions of chronic hepatitis B, hepatitis C patients and HIV infected patients in the standardization of diagnosis and treatment needs, Gilead science and Jinyu medicine will play their respective expertise in the field of treatment and detection, and carry out the detection of chronic hepatitis B HBV DNA Gao Min in the whole country to help patients standardize treatment. Strengthen routine screening of hepatitis C and improve the diagnosis and treatment rate of the disease; Provide renal function and HIV RNA testing for HIV infected people, and provide effective evaluation criteria for long-term treatment for both doctors and patients. In addition, the two sides will cooperate in various forms of doctor education, public health science popularization and patient education, enhance the scientific knowledge of diseases, reduce social discrimination, help chronic hepatitis B, hepatitis C patients and HIV infected persons to better carry out health management and return to normal life.